Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
Authors
Keywords
-
Journal
MOLECULES
Volume 26, Issue 7, Pages 1981
Publisher
MDPI AG
Online
2021-04-01
DOI
10.3390/molecules26071981
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated ABCB1 Expression Confers Acquired Resistance to Aurora Kinase Inhibitor GSK-1070916 in Cancer Cells
- (2021) Zhuo-Xun Wu et al. Frontiers in Pharmacology
- Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and Its Role in the Therapy of Various Types of Cancer through the Modulation of Various Cell Signaling Pathways
- (2021) Saleh A. Almatroodi et al. MOLECULES
- Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
- (2021) Ming Li et al. Cell Death & Disease
- AURKB promotes gastric cancer progression via activation of CCND1 expression
- (2020) Min Nie et al. Aging-US
- Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
- (2020) Jue Jiang et al. CANCER CELL
- Aurora B kinase is recruited to multiple discrete kinetochore and centromere regions in human cells
- (2020) Amanda J. Broad et al. JOURNAL OF CELL BIOLOGY
- Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights
- (2020) Mohammad M. Al-Sanea et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity
- (2020) Ítalo Antônio Fernandes et al. MOLECULES
- Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition
- (2020) Min Huang et al. ONCOGENE
- Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression
- (2020) Naga Rajiv Lakkaniga et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora�B
- (2020) Tomoya Takeda et al. ONCOLOGY REPORTS
- RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis
- (2020) Sara Sánchez-Molina et al. Science Advances
- Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA)
- (2020) Majd S. Hijjawi et al. MOLECULES
- Design, synthesis and molecular docking study of new purine derivatives as Aurora kinase inhibitors
- (2020) Mohamed E. Khalifa JOURNAL OF MOLECULAR STRUCTURE
- FBXW7 in Cancer: What Has Been Unraveled Thus Far?
- (2019) Bethsebie Lalduhsaki Sailo et al. Cancers
- Modelling dose and schedule effects of AZD2811 nanoparticles targeting aurora kinase B for treatment of diffuse large B-cell lymphoma
- (2019) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
- (2019) Sarah Wang et al. CLINICAL CANCER RESEARCH
- A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
- (2019) Melissa Lynne Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CCT137690 on long non-coding RNA expression profiles in MCF-7 and MDA-MB-231 cell lines
- (2019) Tuğçe Balcı Okcanoğlu et al. Bosnian Journal of Basic Medical Sciences
- Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
- (2019) Di Huang et al. Cancer Cell International
- Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells
- (2019) Muhammad Furqan et al. CELL CYCLE
- AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
- (2019) Jordi Bertran-Alamillo et al. Nature Communications
- Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms
- (2019) Keli Lima et al. Scientific Reports
- Targeting Aurora kinase B attenuates chemoresistance in glioblastoma via a synergistic manner with temozolomide
- (2019) Wahafu Alafate et al. PATHOLOGY RESEARCH AND PRACTICE
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy
- (2019) William B. Donnellan et al. BLOOD
- Augmentation of danusertib’s anticancer activity against melanoma by blockage of autophagy
- (2019) Yuan-Yuan Shang et al. Drug Delivery and Translational Research
- Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1/CIP1 mediated pathways
- (2019) Thanigaivelan Kanagasabai et al. CELLULAR SIGNALLING
- Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
- (2018) Swatishree Sradhanjali et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors
- (2018) Michael Carducci et al. INVESTIGATIONAL NEW DRUGS
- A quantitative proteomic response of hepatocellular carcinoma Hep3B cells to danusertib, a pan-Aurora kinase inhibitor
- (2018) Qiaohua Zhu et al. Journal of Cancer
- Dual targeting of aurora kinases with AMG 900 exhibits potent preclinical activity against acute myeloid leukemia with distinct post-mitotic outcomes
- (2018) Marc Payton et al. MOLECULAR CANCER THERAPEUTICS
- The functional diversity of Aurora kinases: a comprehensive review
- (2018) Estelle Willems et al. Cell Division
- An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression
- (2018) Jaewook Ryu et al. Cancer Medicine
- Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells
- (2018) Jian He et al. ANTI-CANCER DRUGS
- A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
- (2018) Hartmut Döhner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Aurora B kinase activity-dependent and -independent functions of the chromosomal passenger complex in regulating sister chromatid cohesion
- (2018) Qi Yi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma
- (2018) Sonali Kumari et al. Nanomedicine
- Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
- (2018) Matthew G. Oser et al. Cancer Discovery
- Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells
- (2017) Sandhya Noronha et al. IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
- Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer
- (2017) Sabrina Schecher et al. INTERNATIONAL JOURNAL OF CANCER
- Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
- (2017) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions
- (2017) Swatishree Sradhanjali et al. PLoS One
- Aurora kinases: novel therapy targets in cancers
- (2017) Anqun Tang et al. Oncotarget
- Aurora B Expression as a Prognostic Indicator and Possibile Therapeutic Target in Oral Squamous Cell Carcinoma
- (2017) G. Pannone et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
- (2016) Klaus Mross et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
- (2016) Si-Jia He et al. CANCER LETTERS
- Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
- (2016) B. A. Helfrich et al. MOLECULAR CANCER THERAPEUTICS
- A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia
- (2016) B. Vormoor et al. PEDIATRIC BLOOD & CANCER
- Quercetin suppresses lung cancer growth by targeting Aurora B kinase
- (2016) Zhu Xingyu et al. Cancer Medicine
- Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
- (2015) Stine Hole et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
- (2015) Graham P. Collins et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells
- (2015) Dan Zi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Spatial Compartmentalization Specializes the Function of Aurora A and Aurora B
- (2015) Si Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of N-(4-(3-(2-Aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), A Highly Selective, Orally Bioavailable Inhibitor of Aurora Kinases with Activity against Multidrug-Resistant Cancer Cell Lines
- (2015) Stephanie Geuns-Meyer et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191
- (2015) Annette E. Hay et al. LEUKEMIA & LYMPHOMA
- The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells
- (2015) Shu-Feng Zhou et al. Drug Design Development and Therapy
- Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma
- (2015) Roberto Jose Diaz et al. Oncotarget
- EBNA3C regulates p53 through induction of Aurora kinase B
- (2015) Hem C. Jha et al. Oncotarget
- Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
- (2015) Dominik Bogen et al. Oncotarget
- A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
- (2015) G. Borthakur et al. HAEMATOLOGICA
- A Cell Biologist’s Field Guide to Aurora Kinase Inhibitors
- (2015) Christian O. de Groot et al. Frontiers in Oncology
- Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model
- (2015) Daniel Benten et al. NEOPLASIA
- Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity
- (2014) Oliver Ou et al. CANCER LETTERS
- Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
- (2014) Carolien Boeckx et al. CANCER LETTERS
- Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
- (2014) Antonino Maria Spartà et al. CELL CYCLE
- A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
- (2014) L. Moreno et al. CLINICAL CANCER RESEARCH
- Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines
- (2014) E. Baldini et al. ENDOCRINE-RELATED CANCER
- RASSF tumor suppressor gene family: Biological functions and regulation
- (2014) Natalia Volodko et al. FEBS LETTERS
- The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy
- (2014) Yan Wang et al. Molecular Cancer
- p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma
- (2014) Zhen Li et al. MOLECULAR CANCER RESEARCH
- Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
- (2014) N. Li et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
- (2014) Anna L. Illert et al. PLoS One
- AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy
- (2014) Ali Zekri et al. TUMOR BIOLOGY
- Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion
- (2014) XIAO PING ZHU et al. Experimental and Therapeutic Medicine
- AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
- (2013) Ondrej Kalous et al. BREAST CANCER RESEARCH AND TREATMENT
- Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
- (2013) Hagop M. Kantarjian et al. CANCER
- Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells
- (2013) Takahiro Yamauchi et al. CANCER SCIENCE
- Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
- (2013) Hagop M. Kantarjian et al. Clinical Lymphoma Myeloma & Leukemia
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
- (2013) James Foran et al. Clinical Lymphoma Myeloma & Leukemia
- Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cellsviaAKT signaling
- (2013) Jing Yang et al. INTERNATIONAL JOURNAL OF CANCER
- NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
- (2013) S. F. Dent et al. INVESTIGATIONAL NEW DRUGS
- Aurora B and Kif2A control microtubule length for assembly of a functional central spindle during anaphase
- (2013) Ryota Uehara et al. JOURNAL OF CELL BIOLOGY
- The pan-Aurora kinase inhibitor, PHA-739358, induces apoptosis and inhibits migration in melanoma cell lines
- (2013) Lifang Xie et al. MELANOMA RESEARCH
- Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
- (2012) Hielke J. Meulenbeld et al. BJU INTERNATIONAL
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
- (2012) Mike Dennis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FBXW7 is involved in Aurora B degradation
- (2012) Chieh-Lin Teng et al. CELL CYCLE
- Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
- (2012) K. Fraedrich et al. CLINICAL CANCER RESEARCH
- Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
- (2012) Gary K. Schwartz et al. INVESTIGATIONAL NEW DRUGS
- Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target
- (2012) S A Hartsink-Segers et al. LEUKEMIA
- Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)
- (2012) Fei Fei et al. Molecular Cancer
- Enhancing Chemosensitivity in ABCB1- and ABCG2-Overexpressing Cells and Cancer Stem-like Cells by An Aurora Kinase Inhibitor CCT129202
- (2012) Chao Cheng et al. MOLECULAR PHARMACEUTICS
- Evolution of Resistance to Aurora Kinase B Inhibitors in Leukaemia Cells
- (2012) Timothy W. Failes et al. PLoS One
- Aurora B kinase phosphorylates and instigates degradation of p53
- (2012) C. P. Gully et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
- (2011) H.- T. Arkenau et al. ANNALS OF ONCOLOGY
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
- (2011) B. Lowenberg et al. BLOOD
- Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
- (2011) A Azzariti et al. BRITISH JOURNAL OF CANCER
- Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide
- (2011) L. Santo et al. CLINICAL CANCER RESEARCH
- Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
- (2011) G. Portella et al. CURRENT MEDICINAL CHEMISTRY
- AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas
- (2011) Wenqing Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells
- (2011) Kleiton Silva Borges et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
- (2011) Kosuke Tsuboi et al. LEUKEMIA RESEARCH
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro
- (2011) Stefan Balabanov et al. PLoS One
- Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
- (2010) D. S. Boss et al. ANNALS OF ONCOLOGY
- Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis
- (2010) Asha Recino et al. BIOCHEMICAL JOURNAL
- Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
- (2010) R. Tanaka et al. BLOOD
- Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state
- (2010) J. den Hollander et al. BLOOD
- Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
- (2010) Zhong-Zhe Lin et al. BMC CANCER
- Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
- (2010) Anne M. Traynor et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Aurora B Interacts with NIR-p53, Leading to p53 Phosphorylation in Its DNA-binding Domain and Subsequent Functional Suppression
- (2010) Liming Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The chromosome passenger complex is required for fidelity of chromosome transmission and cytokinesis in meiosis of mouse oocytes
- (2010) B. Sharif et al. JOURNAL OF CELL SCIENCE
- Discovery ofN-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine Aurora Kinase Inhibitors
- (2010) Shudong Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C Kinase
- (2010) Nicholas D. Adams et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
- (2010) Christopher P Gully et al. Molecular Cancer
- Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer
- (2010) A Pohl et al. PHARMACOGENOMICS JOURNAL
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
- (2010) O. Jameel Shah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
- (2009) Jennifer P. Arbitrario et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
- (2009) R. B. Cohen et al. CLINICAL CANCER RESEARCH
- The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo
- (2009) J. S. Nair et al. CLINICAL CANCER RESEARCH
- Deregulated Aurora-B induced tetraploidy promotes tumorigenesis
- (2009) Hao G. Nguyen et al. FASEB JOURNAL
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
- (2009) Neeltje Steeghs et al. JOURNAL OF CLINICAL ONCOLOGY
- The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma
- (2009) Arihiro Aihara et al. JOURNAL OF HEPATOLOGY
- GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models
- (2009) M. A. Hardwicke et al. MOLECULAR CANCER THERAPEUTICS
- Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152
- (2009) J Guo et al. PHARMACOGENOMICS JOURNAL
- Molecular Basis of Drug Resistance in Aurora Kinases
- (2008) Fiona Girdler et al. CHEMISTRY & BIOLOGY
- Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†
- (2008) Steven Howard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aurora-B Kinase Inhibitors for Cancer Chemotherapy
- (2008) Sai-Ching Yeung et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search